

Listing of the Claims

This listing replaces all prior versions and listings of the claims.

1. (Currently amended) A method for purifying or capturing a non-immunoglobulin protein of interest having between one and ten immunoglobulin-like (Ig-like) domains from a biological fluid, comprising the steps of:
 - a) contacting the biological fluid containing the protein of interest with an Hydrophobic Charge Induction Chromatography (HCIC) resin, wherein the HCIC resin comprises a mercapto-ethyl pyridine ligand
 - b) washing out the resin to remove unbound contaminants, and
 - c) eluting the protein of interest by treating the resin with a solution having an acidic pH or with a solution comprising an organic solvent, wherein the organic solvent is isopropyl alcohol, propylene glycol and/or polyalcohols.
2. (Cancelled)
3. (Previously presented) A method according to claims 1, wherein the organic solvent used in step c) is propylene glycol.
4. (Original) A method according to claim 3, wherein the concentration of propylene glycol in the solution is between about 25 and 50%.
5. (Previously presented) A method according to claim 1, wherein step a) is carried out at acidic pH.
6. (Original) A method according to claim 5, wherein the pH used is between about 3 and 6.8.
7. (Previously presented) A method according to claim 1, wherein the washing of step b) is carried out with a solution having an acidic pH.
8. (Original) A method according to claim 7, wherein the pH used is between about 3 and 6.8.

9. (Previously presented) A method according to claim 1, wherein the biological fluid is selected from a cell-conditioned culture medium, cell lysate, cell extract, tissue extract, blood plasma, serum, milk, urine, ascites, cerebrospinal fluid, vegetable juice, plant extracts or a fraction obtained from an earlier chromatographic separation step.
10. (Previously presented) A method according to claim 1, wherein the protein of interest has 1 to 7 Ig-like domains.
11. (Previously presented) A method according to claim 1, wherein the protein of interest is selected from IL-18BP, NCAM, Fibronectin type III, ICAM-1, mad CAM-1, PE CAM-1, VCAM-1, titin, cadherin, neurocan, LIFR, CNTFR, IL-1R, IL-3R, IL5R, IL-6R, IL-12R, GM-CSFR, OSMR, VEGF receptor, FGF receptor, hPDGF receptor, T cell receptor, MHC proteins, microglobulin- β , CTLA4, B7 activation agent, neuregulin, coagulation factor XIII, NF- κ B, IL6-IL6R, beta-galactosidase and superoxide dismutase or an isoform, mutein, fused protein, or fragment thereof comprising at least one Ig-like domain.
12. (Original) A method according to claim 11, wherein the protein is IL-18 binding protein (IL-18BP).
- 13.-14. (Cancelled)
15. (Previously presented) A method according to claim 1, wherein the purification factor of the eluted protein is in the range of 11 and 94 fold.
16. (Previously presented) A method according to claim 15, wherein the purification factor of the eluted protein is 94 fold.
17. (Previously presented) A method according to claim 1, wherein the concentration factor of the eluted protein is in the range of 1.5 and 3.1 fold.
18. (Previously presented) A method according to claim 17, wherein the concentration factor of the eluted protein is 3.1 fold.
19. (Previously presented) A method according to claim 1, wherein the yield of the eluted protein is in the range of 73 and 98%,

U.S.S.N. 10/567,422

Final Office Action mailed September 12, 2008

Amendment under 37 C.F.R. 1.116 filed December 16, 2008

Advisory Action issued January 6, 2009

2nd Amendment under 37 C.F.R. 1.116 filed February 9, 2009

Page 4 of 5

20. (Original) A method according to claim 19, wherein the yield of the eluted protein is about 85%.

21-45. (Cancelled)

46. (Previously presented) A method according to claim 1, wherein the purification factor of the eluted protein is in about 94 fold.